{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Perspective Therapeutics, Inc.
Is Perspective Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the technical trend is mildly bearish due to daily moving averages indicating bearish sentiment, despite some mixed signals from weekly and monthly indicators, suggesting caution amid significant volatility and a notable decline over the past year.
Who are in the management team of Perspective Therapeutics, Inc.?
As of March 2022, the management team of Perspective Therapeutics, Inc. includes Mr. Michael McCormick (Independent Chairman), Ms. Lori Woods (CEO and Director), Mr. Alan Hoffmann (Independent Director), and Dr. Philip Vitale (Independent Director).
What does Perspective Therapeutics, Inc. do?
Perspective Therapeutics, Inc. is a medical technology company specializing in isotope-based products for cancer treatment. As of March 2025, it reported net sales of $0 million and a net loss of $18 million, with a market cap of $262.03 million.
How big is Perspective Therapeutics, Inc.?
As of Jun 18, Perspective Therapeutics, Inc. has a market capitalization of 262.03 million, with net sales of 1.47 million and a net profit of -84.69 million over the last four quarters. Shareholder's funds are 290.67 million, and total assets are 350.11 million as of Dec'24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
